Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, MD PhD, Alison J. Moskowitz, MD, Neha Mehta-Shah, MD, Lubomir Sokol, MD PhD, Zhengming Chen, PhD MPH, MS, Riyaad Rahim, Wei Song, Koen Van Besien, MD PhD, Steven M. Horwitz, MD, Sarah C. Rutherford, MD, Morton Coleman, MD FACP, Ari Melnick, MD, Giorgio Inghirami, MD, Leandro Cerchietti, MD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136023

Published: 2020

Journal Articles

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134699

Published: 2020

Journal Articles

XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells

Rossella Marullo, MDPhD, Maria Victoria Revuelta, PhD, Nahuel Zamponi, PhD, Sarah C. Rutherford, MD, Peter Martin, FRCPC, MD MS, Giorgio Inghirami, MD, John P. Leonard, MD, Leandro Cerchietti, MD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-141464

Published: 2020

Journal Articles

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

Leandro Cerchietti, MD, Giorgio Inghirami, MD, Nikita Kotlov, PhD, Viktor Svekolkin, PhD, Alexander Bagaev, PhD, Felix Frenkel, PhD, Maria Victoria Revuelta, PhD, Jude M Phillip, PhD, Maria Teresa Cacciapuoti, MS, Sarah C. Rutherford, MD, Peter Martin, FRCPC, MD MS, John P. Leonard, MD

Blood (2019) 134 (Supplement_1): 656.

https://doi.org/10.1182/blood-2019-128889

Published: 2019

Journal Articles

Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth

Jude M Phillip, DPhil, Maria Nieves Calvo Vidal, PhD, Maria Victoria Revuelta, PhD, Nahuel Zamponi, PhD, Stephen Sloan, Benet Pera Gresely, PhD, Tharu Fernando, PhD, Wayne Tam, MD PhD, Giorgio Inghirami, MD, Lawrence Bonassar, PhD, Ari M. Melnick, MD, Leandro Cerchietti, MD

Blood (2018) 132 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2018-99-117774

Published: 2018

Journal Articles

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Peter Martin, FRCPC, MD MS, Nancy L. Bartlett, MD, Julio C. Chavez, MD, John L. Reagan, MD, Sonali M. Smith, MD, Ann S. LaCasce, MD MSc, Jeffrey A. Jones, MD MPH, James Drew, MA, Chengqing Wu, PhD, Leandro Cerchietti, MD, John P. Leonard, MD

Blood (2018) 132 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2018-99-114438

Published: 2018

Journal Articles

Generation and Application of T-Cell Lymphoma Patient Derived Tumor Xenograft Models

Blood (2017) 130 (Supplement 1): 109.

https://doi.org/10.1182/blood.V130.Suppl_1.109.109

Published: 2017

Journal Articles

A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma

Peter Martin, MD, Nancy L. Bartlett, MD, Ildefonso Ismael Rodriguez Rivera, MD, Maria Revuelta, PhD, Julio C. Chavez, MD, John L. Reagan, MD, Sonali M. Smith, MD, Ann S. LaCasce, MD, Lei Zhang, MD, Merry Zhai, BS, Chengqing Wu, PhD, John P. Leonard, MD, Leandro Cerchietti, MD

Blood (2017) 130 (Supplement 1): 192.

https://doi.org/10.1182/blood.V130.Suppl_1.192.192

Published: 2017

Journal Articles

SIRT3 Is a Novel Metabolic Driver of and Therapeutic Target for Chemotherapy Resistant Dlbcls

Meng Li, PhD, Ying-Ling Chiang, PhD, Costas Lyssiotis, PhD, Matthew Teater, PhD, Hao Shen, MD, Ling Wang, MS, Jun Young Hong, BS, Hui Jin, PhD, Cihangir Duy, PhD, Sucharita Mistry, PhD, Leandro Cerchietti, MD, Justin Cross, PhD, Lewis Cantley, MD, Hening Lin, PhD, Ari Melnick, MD

Blood (2017) 130 (Supplement 1): 643.

https://doi.org/10.1182/blood.V130.Suppl_1.643.643

Published: 2017

Journal Articles

HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas

Maria Nieves Calvo Vidal, PhD, Jan Krumsiek, PhD, Jayeshkumar Patel, MS, Shao Ning Yang, Jude M Phillip, DPhil, Rossella Marullo, MD PhD, Tony Taldone, PhD, Giorgio Inghirami, MD, Ari Melnick, MD, Gabriela Chiosis, PhD, Leandro Cerchietti, MD

Blood (2017) 130 (Supplement 1): 645.

https://doi.org/10.1182/blood.V130.Suppl_1.645.645

Published: 2017

Journal Articles

Inhibition of the Integrin αVβ3 Improves the Immune and Anti-Lymphoma Effects of Bexarotene in Cutaneous T-Cell Lymphoma (CTCL)

Maria Florencia Cayrol, Maria Mercedes Debernardi, Maria Victoria Revuelta, PhD, Alejandra Paulazo, Maria Nieves Calvo Vidal, PhD, Jude M Phillip, DPhil, Helena Sterle, Maria Celeste Diaz Flaque, Graciela Cremaschi, Leandro Cerchietti, MD

Blood (2017) 130 (Supplement 1): 732.

https://doi.org/10.1182/blood.V130.Suppl_1.732.732

Published: 2017

Journal Articles

Exportin-1 Connects Dynamic Transcription and Translation of Genotoxic Stress Genes in Diffuse Large B-Cell Lymphoma Patients

Rossella Marullo, MD PhD, Maria Revuelta, PhD, Nahuel Zamponi, PhD, Biljana Culjkovic, PhD, Shao Ning Yang, Haelee Ahn, Giorgio Inghirami, MD, Katherine L. B. Borden, PhD, Leandro Cerchietti, MD

Blood (2017) 130 (Supplement 1): 312.

https://doi.org/10.1182/blood.V130.Suppl_1.312.312

Published: 2017

Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Jia Ruan, MD PhD, Peter Martin, FRCPC, MD MS, Paul J Christos, Dr.P.H., M.S., Leandro Cerchietti, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Wayne Tam, MD PhD, Amelyn Rodriguez, BSN, RN, OCN, David Hyman, Maria Nieves Calvo Vidal, PhD, Lidia Roman Gonzalez, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Morton Coleman, MD, John P. Leonard, MD

Blood (2017) 130 (Supplement 1): 154.

https://doi.org/10.1182/blood.V130.Suppl_1.154.154

Published: 2017

Journal Articles

Development of a Novel Class of Microtubule Destabilizing Agents with Selectivity Against Diffuse Large B-Cell Lymphoma (DLBCL) with B-Cell Receptor (BCR) Activation

Benet Pera Gresely, PhD, Francisco de Asís Balaguer, BS, Mariano Gonzalo Cardenas, PhD, Maria Victoria Revuelta, PhD, Maria Nieves Calvo Vidal, PhD, Rossella Marullo, MD PhD, Nahuel Zamponi, PhD, Ildefonso Ismael Rodriguez Rivera, MD, Yong Ai, PhD, Joseph Fraser Glickman, MSPH, PhD, Isabel Barasoain, PhD, Fernando Díaz, PhD, Ari Melnick, MD, Fengtian Xue, PhD, Leandro Cerchietti, MD

Blood (2017) 130 (Supplement 1): 2546.

https://doi.org/10.1182/blood.V130.Suppl_1.2546.2546

Published: 2017

Journal Articles

The Pro-Tumorigenic Vascular Niche Sustains the T-Cell Acute Lymphoblastic Leukemia Phenotype and Fosters Resistance to Therapy

Blood (2016) 128 (22): 279.

https://doi.org/10.1182/blood.V128.22.279.279

Published: 2016

Journal Articles

Ribavirin, an eIF4E Inhibitor, As a Potential Anti-Lymphoma Therapeutic - Preclinical and Early Clinical Data

Sarah C. Rutherford, MD, Eric Stewart, MD, Tharu M Fernando, MS, Biljana Culjkovic-Kraljacic, Katherine L. B. Borden, Koen van Besien, MD, Peter Martin, MD, Richard R Furman, MD, John P. Leonard, MD, Leandro Cerchietti, MD

Blood (2016) 128 (22): 3045.

https://doi.org/10.1182/blood.V128.22.3045.3045

Published: 2016

Journal Articles

Targeting ß -Catenin Signaling in DLBCL with ICG-001 and PAM-1 Suppresses Cell Proliferation and Induces Apoptosis

Angela A. Fachel, PhD, Ashlesha Shrikant Muley, MS, Cem Meydan, PhD, Xabier Agirre, PhD, Leandro Cerchietti, MD, Ari Melnick, MD, Kristy L. Richards, PhD MD

Blood (2016) 128 (22): 5382.

https://doi.org/10.1182/blood.V128.22.5382.5382

Published: 2016

Journal Articles

RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program

Blood (2016) 128 (22): 739.

https://doi.org/10.1182/blood.V128.22.739.739

Published: 2016

Journal Articles

BCL6 Mediates a Stress Tolerance Phenotype through Its BTB Domain

Tharu M Fernando, MS, Shao Ning Yang, MS, Chuanxin Huang, PhD, Gabriela Chiosis, PhD, Leandro Cerchietti, MD, Ari M. Melnick, MD

Blood (2014) 124 (21): 567.

https://doi.org/10.1182/blood.V124.21.567.567

Published: 2014

Journal Articles

Integrin αvβ3 Transduces Survival and Angiogenic Signals to T Cell Lymphomas and Is a Therapeutic Target

Maria Florencia Cayrol, PhDstudent, Maria Celeste Diaz Flaque, PhD, Tharu Fernando, PhDstudent, Shao Ning Yang, Marcela Bolontrade, PhD, Mariana Amoros, Ricardo Farias, PhD, Giorgio Inghirami, MD, Graciela Cremaschi, PhD, Leandro Cerchietti, MD

Blood (2014) 124 (21): 510.

https://doi.org/10.1182/blood.V124.21.510.510

Published: 2014

NARROW

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Generation and Application of T-Cell Lymphoma Patient Derived Tumor Xenograft Models

A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma

SIRT3 Is a Novel Metabolic Driver of and Therapeutic Target for Chemotherapy Resistant Dlbcls

HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas

Inhibition of the Integrin αVβ3 Improves the Immune and Anti-Lymphoma Effects of Bexarotene in Cutaneous T-Cell Lymphoma (CTCL)

Exportin-1 Connects Dynamic Transcription and Translation of Genotoxic Stress Genes in Diffuse Large B-Cell Lymphoma Patients

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Development of a Novel Class of Microtubule Destabilizing Agents with Selectivity Against Diffuse Large B-Cell Lymphoma (DLBCL) with B-Cell Receptor (BCR) Activation

The Pro-Tumorigenic Vascular Niche Sustains the T-Cell Acute Lymphoblastic Leukemia Phenotype and Fosters Resistance to Therapy

Ribavirin, an eIF4E Inhibitor, As a Potential Anti-Lymphoma Therapeutic - Preclinical and Early Clinical Data

Targeting ß -Catenin Signaling in DLBCL with ICG-001 and PAM-1 Suppresses Cell Proliferation and Induces Apoptosis

RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program

BCL6 Mediates a Stress Tolerance Phenotype through Its BTB Domain

Integrin αvβ3 Transduces Survival and Angiogenic Signals to T Cell Lymphomas and Is a Therapeutic Target

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only